Today's Trend
Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) is receiving a modestly positive signal from analyst estimate revisions, although the company remains unprofitable. The stock has recently traded below its 50-day moving average, suggesting investors may still be focused on ongoing losses and the need for continued funding.
- Zacks Research raised its EPS forecasts across several periods, including FY2026 to $(6.93) from $(6.94), FY2027 to $(6.11) from $(6.16), and FY2028 to $(3.70) from $(3.88). The revisions imply that Agios’ expected losses may narrow more quickly than previously anticipated. Agios Pharmaceuticals analyst estimates
- Quarterly estimates were also improved slightly, including Q4 2026 EPS to $(1.76), Q1 2027 to $(1.59), Q2 2027 to $(1.60), Q3 2027 to $(1.49), Q4 2027 to $(1.42), Q1 2028 to $(1.21), and Q2 2028 to $(1.01). These changes provide a small indication of improving earnings expectations.
- The revisions came from Zacks Research and largely repeat the same underlying report rather than representing a new clinical, regulatory, or commercial development. As a result, they are unlikely to be a major catalyst for AGIO on their own.
- Agios is still expected to report substantial losses: the current-year consensus is $(5.82) per share, while Zacks projects a $(6.93) loss for FY2026. The company’s continued negative earnings and cash-burn risk may limit investor enthusiasm despite the improved forecasts.
Investor takeaway: The estimate increases are mildly supportive and may help explain some interest in Agios, but they reflect slightly smaller expected losses—not profitability. With no new product or pipeline news in these reports, the stock’s weaker performance likely reflects ongoing concerns about losses and the timing of a meaningful earnings recovery.